Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre study to characterize the safety and preliminary efficacy
of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell
acute lymphoblastic leukemia (B-ALL)